CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 19777/S26

CORRESPONDENCE

ZENECA
Pharmaceuticals
A Business Unit of Zeneca Inc.

1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437



HAND DELIVERED

JUN 6 1995

Dr. James H. Short
Division of Cardio-Renal
Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
HFD No. 110, Room No. 16B-30
5600 Fishers Lane
Rockville, MD 20857

NDA NO. 19-777 SUPPL NO. S-02
NDA SUPPL FOR SCS

Dear Dr. Short:

Re: ZESTRIL® (lisinopril dihydrate)
NDA 19-777

The purpose of this submission is to provide the Agency data to support the change of solvent used in the manufacture of the lisinopril TFA ester used in the manufacture of lisinopril dihydrate. The currently approved supplier of lisinopril TFA ester uses as the solvent in the manufacturing process. As a result of the "Montreal Protocol," the supplier is proposing to change the solvent used for the manufacture of lisinopril TFA ester to a mixture of

Attachment 1 contains a summary of the change.

Attachment 2 provides the old and new specifications for the lisinopril TFA ester. The currently approved specifications for lisinopril dihydrate have not changed from that currently approved and are provided for your convenience.

Attachment 3 contains comparative batch analyses on four batches of lisinopril TFA ester manufactured with the old and new solvents. Additionally, comparative batch analyses have been provided for three batches of lisinopril dihydrate manufactured with lisinopril TFA ester manufactured with both the old and new solvents.

The applicant hereby commits to place the first batch of each dosage strength of drug product into its commercial stability program and report the results to the Agency in the applicant's Annual Reports.

The applicant hereby certifies that a copy of this submission was submitted, in accordance with 21 CFR 314.70(a), to the Philadelphia District Office.

ORIGINAL

If you should require additional clarification or information, please do not hesitate to contact me.

Sincerely,

Robert Castor
Manager, Marketed Products Group
Drug Regulatory Affairs Department
(302) 886-2594
(302) 886-2822 (fax)

RC/SPT/jr/3222/76
Enclosures